Prokarium acquires key oral vaccine technology from Emergent BioSolutions
Emergent has successfully conducted several phase 1 and 2 clinical trials, which have shown TyphellaTM to be safe and immunogenic as a typhoid vaccine. The combination with Prokarium’s plasmid stabilisation technology ORT-VACTM, will enable the delivery of recombinant protein vaccines without needles or adjuvants. Prokarium plans to offer this VaxonellaTM platform to the biotech community on a licensing basis.
Prokarium will focus on the development of a dual oral vaccine against typhoid and ETEC (enterotoxigenic E. coli) for travellers and developing country markets.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.